Kerri Fitzgerald

DocwireNews

For many years, patients with advanced <a href="https://proddocwire.wpengine.com/docwire-pick/decreased-risk-ovarian-cancer/">ovarian cancer</a> underwent systematic pelvic and paraaortic lymphadenectomy. Despite debate over the necessity of the procedure, some studies reported that lymphadenectomy was associated with improved survival. However, according to the international, multicenter LION (lymphadenectomy in ovarian neoplasms) study published in The New England Journal of Medicine, this approach is not associated with longer overall survival (OS; primary endpoint) or progression-free survival (PFS) compared with patients who do not undergo lymphadenectomy.The researchers assessed 647 patients with newly diagnosed advanced <a href="https://proddocwire.wpengine.com/docwire-pick/nsaid-improves-ovarian-cancer/">ovarian cancer</a> (International Federation of Gynecology and Obstetrics stage IIB-IV) who had undergone macroscopically complete resection and had normal lymph nodes both before and during surgery. Patients were intraoperatively randomized between December 2008 to January 2012 to either undergo (n=323) or not undergo (n=324) lymphadenectomy.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms | NEJM <a href="https://t.co/vr3p1oFanv">https://t.co/vr3p1oFanv</a> &ndash; key surgical RCT. Systematic LN dissection no longer required in advanced ovarian ca &ndash; demonstrates the importance of surgical trials
&mdash; Donal Brennan (@donalb5) <a href="https://twitter.com/donalb5/status/1101008089459945472?ref_src=twsrc%5Etfw">February 28, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><h2>Survival not improved with lymphadenectomy</h2>Among patients who underwent lymphadenectomy, the median number of nodes removed was 57 (35 pelvic and 22 paraaortic nodes). There was no improvement in survival among patients who underwent lymphadenectomy: The median OS was 69.2 months in those who did not undergo the procedure versus 65.5 months in those who did (hazard ratio [HR] for death in the lymphadenectomy group = 1.06; 95% CI, 0.83-1.34; P=0.65). The median PFS was 25.5 months in both groups (HR for progression or death in the lymphadenectomy group = 1.11; 95% CI, 0.92-1.34; P=0.29).<h2>Postoperative complications mount in lymphadenectomy group</h2>Patients in the lymphadenectomy group reported more serious postoperative complications, including incidence of repeat laparotomy (12.4% vs 6.5%; P=0.01) and mortality within 60 days after surgery (3.1% vs 0.9%; P=0.049). The most common reason for repeat laparotomy was bowel leak or fistula.&ldquo;Patients with advanced ovarian cancer &hellip; did not benefit from systematic lymphadenectomy,&rdquo; the researchers concluded.https://twitter.com/DrAnojanMD/status/1101018964648517632

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Study Overturns Previous Thinking on Lymphadenectomy in Patients With Ovarian Cancer

Ovarian Cancer

For many years, patients with advanced ovarian cancer underwent systematic pelvic and paraaortic lymphadenectomy. Despite debate over the necessity of the procedure, some ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe